Life Sciences Archive » June, 2023

Life Sciences - June, 2023

355 articles

• Opioid Judge Mulls Liability Of 'Don Draper' McKinsey
• Biz Group Presses Tai On Lingering Mexico Trade Frictions
• Talc Claimants Call J&J Unit's 2nd Ch. 11 A Tort Dodge
• EU, Pfizer Strike Pandemic Prep Deal Via €5B Health Program
• Feds Deny Liability For ICE Detainee's COVID-19 Death
• Amgen, Horizon Lodge Constitutional Attack On FTC
• Gilead, Teva Defeat $3.6B HIV Drug Antitrust Case At Trial
• DC Circ.'s Perchlorate Ruling Means Regulatory Restart
• Once-Dreary IPO Outlook Brightens For Second Half Of 2023
• Appellate Funding Disclosure: No Mandate Is Right Choice
• The Fed. Circ. In June: A Lesson On Citing With Particularity
• UK Litigation Roundup: Here's What You Missed In London
• Wachtell Guides Bausch & Lomb In $2.5B Novartis Deal
• Justices Order FCA Do-Overs After SuperValu Intent Ruling
• What IP Attys Need To Know About Del. Judge Nominee Hall
• Calif.'s Insulin Cost Suit Against CVS Sent Back To State Court
• Pharma CEO, Others Get Prison Time In $80M Medicare Fraud
• Bans On Trans Youths' Health Care Get Blocked In Tenn., Ky.
• Tennessee Accuses 3M, DuPont Of PFAS Foam Contamination
• Ex-Alexion VP, Police Chief Charged In Insider-Trading Sweep
• DOJ Fights AmerisourceBergen's Dismissal Bid In Opioid Suit
• Case Law Is Mixed On D&O Coverage For Gov't Investigations
• Atty For Theranos Exec Joins Seattle's Corr Cronin
• COVID Drug Maker Tevogen To Go Public Via SPAC At $1.2B
• Eli Lilly To Buy Mass. Biopharmaceutical Biz For Up To $300M
• Key PTAB Priorities And Changes Under Vidal
• Pfizer Insider Charged With Profiting Off COVID Drug Info
• J&J Took Initiative On 2019 Talc Recall, Jury Hears
• Attys For Gilead, Drug Buyers Trade Barbs As $3.6B Trial Ends
• Accused Atty Says Feds' Theory Faulty In Biz Takeover Case
• Judge Says Full Freeze Of NC Abortion Law Is 'Off The Table'
• Judge Says Pharma Industry Has 'Perverted' Hatch-Waxman
• DOJ Targets Telehealth, Opioids In $2.5B Fraud Sweep
• Eligibility Bill Gives Attys Relief, Even With 'Squishy' Terms
• Sanofi Clears Cancer Drug From More Generic Competition
• UK Health Co. Wants Out Of US Psilocybin Therapy Theft Suit
• FTC Order May Guide Cos. In Avoiding Pyramid Scheme Label
• Preparing For FDA's Surprise Foreign Drug Inspection Regime
• Drug Pricing Law Could Have Unintended Consequences
• DePuy Wins Pa. Spinal IP Infringement Case Mid-Trial
• Pierre Fabre Can't Clean Out All Of Benzene Shampoo Suit
• What's Next For Colorado's Psychedelics Legalization?
• HIV Drug Buyers Urge $3.6B Verdict Against Gilead And Teva
• Abortion Providers And SC Fight Before State's Top Court
• AliveCor Asks Fed. Circ. To Flip Partial Loss In Apple ITC Row
• Medtronic Rival Defends Surgical Device Antitrust Case
• J&J Talc Unit Dismissal Trial Focuses On Funding Agreements
• Mass. Pharmacy To Pay $10M For Missing Opioid 'Red Flags'
• 2 Reps. Float House Companion To Senate PTAB Overhaul Bill
• Paratek Investor To Withhold Board Votes, Citing Concerns
• PTAB Rightly Axed Medytox Wrinkle Patent, Fed. Circ. Says
• SuperValu's Lesson: Always Be Building An FCA Defense
• Texas Firms' Paxil Fee Fight Survives Anti-SLAPP Challenge
• McCarter & English Adds Former J&J Deputy General Counsel
• Dentons Adds IP Pro From Steptoe & Johnson
• NBA Players Must Avoid Legal Fouls In CBD Deals
• Upside For Advertisers After 2nd Circ. False Ad Suit Revival
• Cellino Can't Get Fees From Ga. Mesh Lawsuit, Atty Claims
• NC Dental Board Wants To Ax Kroger's Ohio Opioid Subpoena
• Supreme Court's Opioid Edict Spawns 'Troubling' Divisions
• 3 Ways New Senate Bill Would Reshape PTAB Litigation
• Gilead Didn't Pay Teva In HIV Drug IP Deal, Economist Says
• Attys Want $76M After $255M Juul Settlement
• Judge Lets NC Republican Leaders Jump Into Abortion Suit
• Detroit Tigers, Fired Employee Must Mediate Civil Rights Suit
• Dechert, Shearman Rep On MedTech's $370M SPAC Merger
• Optum To Buy Amedisys For $3.3B, Derailing Option Care Deal
• A Comprehensive Overview Of PTAB Trends For Biologics
• Astellas, Aon Ink $9.5M Deal In Suit Over 401(k) Management
• 3M Strikes Confidential PFAS Deal With Fla. City
• Insys Founder Kapoor Released After 2 Years In Prison
• Shkreli-Linked Pharma Co. Strikes Deal Over Share Sale
• No Jurisdiction In 2 Cook Medical MDL Suits, Panel Rules
• Fed. Circ. Decision Offers Lessons In Analogous Art Tests
• Mallinckrodt To Make Payments On $1.7B In Term Loans
• Walmart Investors Balk At Stay Request In Del. Opioid Suit
• How Attys Can Avoid Exposing Their Firms To Cyberattacks
• Catching Up With Delaware's Chancery Court
• A Need To Be Big: US Law Firms Kept Foot On Gas In 2022
• 10 Years Of The 10 Biggest US Firms
• The Law360 400: Tracking The Largest US Law Firms
• Ark. Pot Biz Urges 8th Circ. To Revive Discrimination Suit
• Attys Tell Biden Admin Pot's Schedule 1 Status 'Indefensible'
• McKinsey Nears Opioid MDL Deal With Tribes, Insurance Plans
• Ex-FTC Official Pans Claim Gilead-Teva Deal Hurt Competition
• CVS Settles Calif. Ex-Pharmacy Tech's Disability Bias Suit
• Biden Orders DOL To Expand Birth Control Access
• NC Republican Leaders Want To Jump Into Abortion Ban Suit
• Health Hires: MapLight, Wilson Sonsini, Mayer Brown
• 3 Questions Lingering For Benefits Attys 1 Year After Dobbs
• 6 States Join FTC's Challenge To Amgen's $28B Horizon Buy
• NM High Court Clarifies State's Rules On Duplicative Damages
• AG's Eli Lilly Insulin Probe Needs Mich. High Court Action
• Rare FDA Move Shows Stance On Remote Monitoring Devices
• Ex-Trulieve Pot Biz Worker Says He Was Fired For FMLA Leave
• ExecuPharm Must Face Claims In 'CL0P' Hacking Case
• Chinese Chemical Cos. Charged In Major Fentanyl Bust
• PharmacyChecker Defends Blacklist Suit Against LegitScript
• Pa. Pharmacy Knew Doc Overprescribed Meds, Woman Says
• Icon Ken Feinberg Shares Lessons From A Life Mediating
• Princeton Wins Bid To Depose Professor In Manuscript Battle
• NJ Law Firm Hit With Malpractice Claims Over Atty Fees
• What Purdue Ch. 11 Means For Future Of Third-Party Releases
• Trial Set In Ga. Woman's Pelvic Mesh Case
• Virginia 'Rocket Docket' Slowdown Is Likely A Blip
• FDA Publishes Draft Guidance On Psychedelic Drug Research
• UK Litigation Roundup: Here's What You Missed In London
• Taxation With Representation: Latham, Kirkland, Fenwick
• Tillis, Coons Bills Aim To Limit Invalidation Rulings
• Jazz Pharma Says FDA Again Defied Orphan Drug Exclusivity
• How Dobbs Has Changed The Data Privacy Landscape
• ArcherDX Says Natera Dragged Feet On Patent Filings
• NC AG Agrees With Those Suing Him: Abortion Ban Unlawful
• J&J Talc Unit's Ch. 11 Suit Injunction Extended To August
• How A Top Anti-Abortion Atty Sees Dobbs 1 Year Later
• How A Top Abortion-Rights Atty Sees Dobbs 1 Year Later
• Abortion Litigation To Watch As Dobbs Decision Turns 1
• State Lawmakers Reveal How They Move Psychedelics Policy
• Lozenge Buyers Push Back On P&G Bid To Toss False Ad Suit
• 3M Strikes $12.5B Deal Over PFAS Contamination
• Lyme Disease Test 'Useless,' 'Inaccurate,' Suit Says
• Preparing For Md. Adult-Use Cannabis: Operations And More
• Applying Hatch-Waxman To Cell And Gene Therapies
• Ex-Jurist's $1,550-Hour Gilead Witness Job Not Ethics Issue
• Feds Fight Gilead's Win In Billion-Dollar HIV Patent Trial
• Drug Lobby Widens Industry Pricing Challenges To Texas
• Va. Judge Revives 2 Patents Axed In $17M Bone Screw Trial
• IAnthus Stole $4.5M From Cannabis Co., Suit Claims
• Sandoz Fights $39M Loss In Suit Over Eyelash Growth Serum
• 7th Circ. Reverses Ceramic Co.'s Win In Asbestos Suit
• 11th Circ. Backs Vacating Arb. Award In Medical Device Fight
• Millennium Lab Trust Needs More Time For $1B JPMorgan Suit
• Where State Abortion Ballot Measures Stand After Dobbs
• 5th Circ. Backs Collective Cert. In Therapists' OT Suit
• FTC Urges 2nd Circ. To Revive Bystolic Antitrust Case
• Zoetis Seeks Access To Stable In Antibiotic Horse Death Suit
• Vanda Asks Full Fed. Circ. To Review Axed Sleep Med Patents
• Attys Say 'Fractured' Pot Reform A Lesson For Psychedelics
• PTAB OKs Most Of Amended Patent On Transport Containers
• Texas District Attys Want Abortion Ban Challenge Dismissed
• Preparing For Md. Adult-Use Cannabis: Licensing Provisions
• FTC's Amgen-Horizon Protest Raises Conglomerate Concerns
• Gilead-Teva Deal Costs To Buyers Top $3.6B As Plaintiffs Rest
• 7th Circ. Backs TRT-Maker Actavis In Man's Heart Attack Suit
• 2 Firms Will Steer FibroGen Stockholder Suit In Chancery
• Supreme Court Remands Medicaid Rows To 4th, 7th Circs.
• Sanofi Needn't Indemnify German Pharma Co. In Zantac Suits
• Senate Confirms Abortion Rights Atty To 1st Circ.
• High Court Underscores DOJ's Role In Policing FCA Litigation
• Republicans Keep Up Complaints About WTO COVID Waivers
• 'No Settlement' Coming In Pharma Tech Exec's Contract Suit
• 5 Management Tips To Keep Law Firm Merger Talks Moving
• What 3rd Circ. Niaspan Decision Means For Class Cert.
• AI-Focused Spinal Imaging Co. Hits Ch. 11 After Layoffs
• 2 Firms Build $2.4B Sale Of SF Biopharmaceutical Biz
• Conn. Atty Wants New Judge After Polling Gaffe In SEC Case
• Law360 Names 2023's Top Attorneys Under 40
• Calif. Jury Finds Urologist Stole Penile Implant Trade Secrets
• Bristol-Myers Joins Big Pharma Attack On Price Negotiating
• Harvard Profs Battle Over $1.5B Antitrust Damages Estimate
• High Court's FCA Ruling Reopens Constitutionality Question
• Arthrex Loses Bid For Director Review Of 2017 PTAB Ruling
• Wash. Judge Tosses Chilean Co.'s Row With Supplier
• Outcome Ex-CEO Fights Forfeiture After $1B Fraud Conviction
• Walgreens Must Face Bulk Of Kids' Cough Medicine Suit
• Pharma Co. Sues To Stop Sale Of Shkreli's Shares In Ch. 11
• Iowa Supreme Court Blocks Fetal Heartbeat Abortion Ban
• Providers Sue To Undo 'Nonsensical' NC Abortion Limits
• Vidal To Scrutinize Ax Of 5 Patents Over Withheld Data
• Cava's Scorching Debut Could Help Thaw A Frozen IPO Market
• Kaiser Permanente Gets Tax Credit Claims Cut Permanently
• AngioDynamics Wants Atty Fees From Bard In Patent Case
• Ga. Doc Liable For Metal Poisoning False-Billing Scheme
• SmileDirect Drops Antitrust Suit Against Calif. Dental Board
• Purdue Seeks Ch. 11 Stay Extension To Implement Its Plan
• Texas High Court To Take On Fen-Phen Atty Malpractice Fight
• Recent Bills Show Congress' Growing Maturity On Cannabis
• Immunomedics Attys Win $12M Fee In $40M Data Scandal Deal
• Law360's 2023 Life Sciences Editorial Advisory Board
• UK Litigation Roundup: Here's What You Missed In London
• High Court Backs Broad FCA Dismissal Authority For Gov't
• Amgen, Samsung Test Blood Drug Patent In 'Biosimilars' Race
• Penile Implant 'Trade Secrets' Are Urology 101, Jury Told
• PwC Must Face Valeant Investor Suit Over Missed 'Red Flags'
• Hospital Hit With $8M Verdict Over Botched Cesarean Section
• Prominent Kirkland Litigator Steps Away From Practicing Law
• Hospitals Seek Class Counsel In Opioid MDL
• Inovio Investors Get Derivative Deal OK'd Over Vaccine Claims
• IP Forecast: It's Deja Vu In $2.75B Cisco Patent Row
• AbbVie Unit Launches Patent Suit Over Cancer Drug
• Colgate-Palmolive Wants Justices To Undo $300M ERISA Loss
• Group's Delay Enforcing $500K Deal Draws Judge's Scrutiny
• Bestway Offers Store Sales Over CMA Deal Concerns
• What The Data Says About FDA Responses To FOIA Requests
• Cybersecurity Is Biggest Compliance Threat, Survey Says
• LabMD's Malpractice, Fraud Claims In Ga. Sent To Arbitration
• Fed. Circ. Args Don't Bode Well For Patent Term Adjustment
• The Texas Two-Step May Be Losing Steam
• NY AG Inks $6.9M Deal Over Roundup Safety Ad Claims
• Battery Tech Firm Cancels SPAC Merger As More Deals Fail
• Mallinckrodt Skips Bond Interest Bill While Mulling Options
• Perkins Coie Adds DC Partner, Building Food Industry Focus
• FTC Pharma Merger Digest May Offer Policy Clues
• The Road Ahead For Rite Aid And Other Troubled Retailers
• EEOC Drops Age Bias Suit Over Novo Nordisk Transfer Denial
• Reed Smith Continues Partner Hires With Investment Pro
• Ex-FDA Official Tells Antitrust Jury Generic Rivals Were Ready
• PBM Trade Group Balks At Move To Curtail Compensation
• Drop In Ransomware Attacks Boosts Cyber Insurers In 2022
• Ex-ADI Engineer Asks To Delay Prison During 1st Circ. Appeal
• Fed. Circ. OKs Denial Of Blood Pressure Treatment Patent App
• 3 Abortion Enforcement Takeaways 1 Year After Dobbs
• Rethinking In-Office Attendance For Associate Retention
• 4 Paths To Defending Calif. Unfair Competition Claims
• Lawmakers Push FDA To Finish E-Cig Applications
• UC Fights Teva's Bid To Invalidate Prostate Cancer Patent
• Fintiv Discretionary Denials Seem To Be Back At PTAB
• Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told
• Spinal Device Co. Gets $6M Bond Cut In Trade Secrets Suit
• Monsanto's 11th Circ. Appeal Deal Queried In Roundup Case
• Ch. 11 Dismissal Trial A Gating Issue In J&J Talc Unit Case
• Holmes Opposes Feds' Post-Prison Victim Payment Plan
• Biotech Co. Says SEC Can't Back Up Asset Freeze
• DOJ's 'Hyperbolic' Opioid Suit 'Falls Far Short,' Rite Aid Says
• GOP Lawmakers, AGs Back Illumina Against FTC At 5th Circ.
• What Innovators Can Expect In The Patent World After Amgen
• Cooley, Latham Steer Turnstone Biologics' $86M IPO Filing
• Crowell & Moring Exiting Walgreens Suit Over Conflict Claims
• DOJ Sees Far-Reaching Victory In High Court's FCA Ruling
• Software Fair Use Protections Attacked At DC Circ.
• Hospitals Call Ex-Doctor's Challenge To Vax Deal 'Mudslinging'
• Amgen, Horizon Blast FTC's 'Speculation On Speculation'
• Bladder Drug Patent Fails To Survive In Del.
• Despite Its Plan Objections, UST Also Won In Purdue Ch. 11
• Icahn's Persistence On Illumina Pays Off With Series Of Wins
• Catching Up With Delaware's Chancery Court
• USPTO's Speed On Some China Patents Bears A Closer Look
• Mont. AG Latest To Question National Org. Over Funds Use
• Ex-GC Accuses Health Tech Co. Of Toxic Environment
• As Tech Market Heats Up, More Firms Are Ready For Denver
• Murdaugh Trials Offer Law Firms Fraud Prevention Reminders
• DLA Piper Litigator Jumps To Arnold & Porter In Houston
• Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told
• 'I Get Upset,' Penile Implant Doc Apologizes To Judge, Jury
• Big Biz Brings New Challenge To HHS Drug Price Negotiations
• LabMD Hit With Sanctions Bid Over Ga. Lawsuit
• FibroGen Investors Seek Sanctions For Destroyed Evidence
• Rival Presses Treble Damages Bid Against Philips Medical
• 1st Circ. Upholds Vitamin Shoppe's Win In Muscle Powder Suit
• 9th Circ. Nixes P&G False Ad Suit, Calls Label 'Concerning'
• Del. Justices Uphold Atty Fee Denial In Mooted Novavax Suit
• Pfizer Mismanaged Fees For $22B 401K Plan, Employees Say
• Boston Scientific Wins $158M In Cook Medical Patent Trial
• What Courts Say About Workers' Comp And Medical Marijuana
• Pharmacy Compliance Exec Guilty Of $50M Medicare Fraud
• AstraZeneca, Quell Make Collaboration Deal Worth Up To $2B
• UK Litigation Roundup: Here's What You Missed In London
• New Mexico Inks $500M Opioid Deal With Walgreens
• Lowenstein Sandler Criticized In Conn. Biz Document Dispute
• Group Backs Illumina Attack On FTC Structure At 5th Circ.
• Chilean Co. Asks Court To Stop Supplier's Sales To Rival
• Cherokee Nation Sues Opioid Distributor After DEA Discipline
• IP Forecast: Google To Face $33M Audio Patent Trial
• FTC Mulling Juul-Altria Settlement Offer Staffers Oppose
• Japanese Pharma Giant Eisai Hit By Ransomware Attack
• Lannett Gets OK For $511M Debt-Swap Ch. 11 Plan
• NY AG Sues Anti-Abortion Group For Interfering With Clinics
• MiMedx Execs To Pay SEC Nearly $2M To End Fraud Claims
• Tribe, Green Groups Say Fruit Company Is Polluting Wetlands
• AI-Fueled Innovation Poses Patentability Challenges
• Nevada, Teva Ink $193M Deal Over Opioid Crisis
• CVS Must Face Insulin Price Suit In State Court, Calif. Says
• Teva Atty Says Gilead Deal Followed Bad News On FDA Filing
• Senators Try To Come To Grips With AI Inventorship
• Ex-Insys CEO Says Legal Fee Clawback Unsupported In Ch. 11
• PharmacyChecker Denied Appeal After Blacklist Suit Tossed
• Judge Reverses Course On Jurisdiction In False Ad Suit
• Pot Cos., Advocates Partner To Push Cannabis Rescheduling
• Amazon Teams Up With Canon, Yeti On Joint Counterfeit Suits
• Firm Tips For Helping New Lawyers Succeed Post-Pandemic
• Crowell & Moring Blasted Over Fees Clause In Walgreens Suit
• SPAC Extends Merger Timeline After Investors Redeem $11M
• What To Know About Recent Trends In PTAB Sanctions
• Ultrasound Tech Co. Must Face Fujifilm's Patent Claims
• Biopharma Co. Hit With Firing Bias Suit Over COVID Vax Rules
• Pfizer, Moderna Sued Over MRNA Tech In COVID Vaccines
• Merck Brings Jones Day Brawler & Punchy Tone To HHS Fight
• Providers Challenge Kansas Abortion Restrictions
• Ex-Gilead GC Says He Didn't Calculate Teva's Gain In IP Deal
• Judge Hesitant To Advise Michigan Justices On Insulin Probe
• Alkermes Raises Revenue Forecast After Arbitration Award
• Wash. Panel Disputes J&J Analysis On Protecting Health Data
• TRIPS Vaccine Waiver Was A Bad Call, GOP Reps. Say
• Case Against Takeda, Eli Lilly Gets Partial Class Cert.
• Talc Claimants Object To Fee Deal For J&J Plan Supporters
• Illumina Tells 5th Circ. Grail Case 'Flagrant' Overreach
• Fate Execs Sued After $50M Deal With J&J Unit Falls Apart
• Prepping Your Business Ahead Of Affirmative Action Ruling
• AI-Focused Biotech Seeks Chapter 11 To Rework $9M Debt
• 4 Emerging Risks For US Insurance Markets
• Judge Blocks Fla. Ban On Trans Health Care
• 3 Firms Build $462M Sale Of Paratek Pharmaceuticals
• Ex-Gilead VP Says Execs Gamed Out Truvada Generic Date
• Circuits 'Didn't Get The Memo' On Opioid Cases, Justices Told
• Mallinckrodt Considers New Bankruptcy Over Opioid Payment
• Chancery Won't DQ Selendy Gay In Fortis-J&J Earnout Suit
• 3rd Circ. Rejects Rehearing Bid From Niaspan Buyers
• Shareholders, Regulators Urge Rejection Of Clovis Ch. 11 Plan
• JPML Consolidates Thyroid Drug Hearing-Loss Suits In Illinois
• Ex-Ascension Doc Says Mich. Settlement Thwarts Indiana Suit
• Psychedelics Bill Roundup: Nevada OKs New Working Group
• Amedisys Mulls $3.2B Optum Bid Despite Option Care Deal
• Tackling Judge-Shopping Concerns While Honoring Localism
• Medtronic Loses Catheter Patent Fight At Fed. Circ.
• J&J Wants Review Of Talc Attys' Media Contact Subpoenas
• 3 Firms Lead CERo Therapeutics $145M SPAC Merger
• 3 IP Attys Join Cooley From Fish & Richardson
• 8th Circ. Won't Revive Heart Valve Contract Dispute
• Judge Calls Apple's Conduct In Smartwatch Row 'Careless'
• Premera Joins Takeda Antitrust Litigation Over IBS Drug
• BioMarin Hit With Del. Derivative Suit Over Missed Deadline
• Care One Fired Sales Rep For Compliance Concerns, Suit Says
• Mich. Appellate Judges Split On COVID Tolling Orders
• NJ Lab CEO Accused Of Wrecking Rival Lab's Hardware
• Lannett Reaches Deal With Creditor Committee In Ch. 11
• No Easy Out For FCA Defendants After Justices' Ruling
• How Telemedicine Providers Can Adapt To Post-COVID Rules
• Fed. Circ. Urged To Undo $2.3M Bone Imaging IP Verdict
• Surge In Secondary Offerings Raises Hopes For IPO Rebound
• Is SEC's Universal Proxy Rule Living Up To The Hype?
• How Attorneys Can Help Combat Anti-Asian Hate
• US Moves Toward Legal Dispute Over Mexico's Corn Policy
• AGs Cut $102M Deal With Indivior In Suboxone Antitrust Case
• Morgan Lewis Adds Life Sciences Atty From Goodwin Procter
• UK Litigation Roundup: Here's What You Missed In London
• Congress Needs To Enact A Federal Anti-SLAPP Statute
• Thomas Burnishes False Claims Act Crown With 9-0 Decree
• Sorrento Ends LA Times Owner's Drug Claims, For Now
• J&J Tells Jury 1970s Talc Findings Irrelevant Now
• High Court Opens Up Uncertainty On FCA Recklessness
• FTC Wants 5th Circ. To Slow Down Illumina's Grail Appeal
• Congress Proposes Permanently Lifting Baby Formula Duties
• Judge Wipes Out Bard's Jury Win In Medical Device IP Feud
• Ax Of 5 Patents Shows PTAB's Hard Line On Duty Of Candor
• Gov't Told To Keep Fighting 'Unexpected' HIV Patent Loss
• 62 Lawmakers Call To Escalate Corn Dispute With Mexico
• Georgia Drops Federal Contractor Vaccine Case Against Biden
• DC Judge Rips Crowell Attys Over Walgreens-Humana Fight
• Philips Scoffs At Rival's Bid For Treble Damages After IP Trial
• Former FDA Official Joins Morgan Lewis In DC
• Global Issues In EU's Licensing Plans For Essential Patents
• Bristol-Myers, Fired Workers End COVID Vax Bias Suit
• Justices Say FCA Liability Hinges On Defendants' Beliefs
• Biotech Biz Buys COVID Test Kit Maker For £10.4M
• LivaNova Hits Back In €21M Suit Over Heart Biz Acquisition